Specifically, type I interferons (IFN) have been shown to enhance the cytotoxicity of tumor associated neutrophils through increased ROS production and NET formation in mouse models, and this neutrophil activation was also shown in melanoma patients undergoing type I IFN therapies56. The gene discussed is IFNA1; the disease is melanoma.